DSGN
Design Therapeutics, Inc.Company Information
- Company Name
- Design Therapeutics, Inc.
- CIK
- CIK0001807120
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- DSGN: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- DSGN
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-03-25
- Last sale
- 2025-08-13
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 566,433
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 43,003,333
- Shares outstanding
- 62,505,340
- Ownership
- 68.80%
Earnings Market Reaction
- Filing date
- 2026-08-03
- Price on filing date
- —
- 1-month reaction
- 18.42%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 13 | 13 | 17 | 15 | 20 | 14 | 23 | 30 | 46 | 29 | 21 | 28 | ||||||
| Marketable Securities Current | 194 | 210 | 203 | 191 | 197 | 216 | 223 | 224 | 215 | 241 | 261 | 263 | ||||||
| Prepaid Expense And Other Assets Current | 5 | 4 | 4 | 3 | 4 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | ||||||
| Assets Current | 212 | 227 | 224 | 209 | 220 | 234 | 248 | 257 | 265 | 274 | 285 | 295 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | ||||||
| Operating Lease Right Of Use Asset | 2 | 3 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | ||||||
| Other Assets | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 215 | 230 | 226 | 212 | 223 | 237 | 252 | 262 | 270 | 279 | 290 | 300 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 2 | 2 | 2 | 1 | 3 | 2 | 1 | 1 | 1 | 2 | 2 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | 8 | 8 | 11 | 9 | 8 | 5 | 6 | 6 | 5 | 6 | 8 | 10 | ||||||
| Liabilities Current | 11 | 10 | 13 | 11 | 9 | 8 | 8 | 7 | 6 | 7 | 10 | 12 | ||||||
| Operating Lease Liability Noncurrent | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | ||||||
| Liabilities | 13 | 12 | 14 | 12 | 10 | 10 | 10 | 9 | 8 | 9 | 12 | 15 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 537 | 533 | 509 | 480 | 477 | 472 | 469 | 465 | 462 | 458 | 455 | 452 | ||||||
| Retained Earnings Accumulated Deficit | -335 | -315 | -297 | -281 | -264 | -245 | -227 | -214 | -201 | -189 | -178 | -166 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -0 | 0 | 0 | 0 | 0 | 0 | 1 | -0 | -0 | 0 | -1 | ||||||
| Stockholders Equity | 202 | 218 | 213 | 200 | 213 | 228 | 242 | 252 | 261 | 270 | 278 | 285 | ||||||
| Liabilities And Stockholders Equity | 215 | 230 | 226 | 212 | 223 | 237 | 252 | 262 | 270 | 279 | 290 | 300 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 63 | 62 | 60 | 57 | 57 | 57 | 57 | 57 | 57 | 56 | 56 | 56 | ||||||
| Shares Outstanding | 63 | 62 | 60 | 57 | 57 | 57 | 57 | 57 | 57 | 56 | 56 | 56 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialDesign Therapeutics, Inc. (DSGN) — SEC Financial Statements & Analysis
Design Therapeutics, Inc. (DSGN) is a pharmaceutical preparations company, incorporated in DE. Design Therapeutics, Inc. trades on Nasdaq as: DSGN. Design Therapeutics, Inc. (DSGN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-03. Based on that filing, Design Therapeutics, Inc. carries a market cap of $904.45M, a P/E ratio of -12.78x, a P/B ratio of 4.48x, an enterprise value of $891.55M, and an EV/EBITDA multiple of -11.32x. On profitability, it posts a Return on Equity (ROE) of -34.13%, a Return on Assets (ROA) of -32.33%, and a Return on Invested Capital (ROIC) of -41.52%. Per share, it reports EPS of $-1.13, diluted EPS of $-1.13, free cash flow per share of $-0.88, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 11.51% year-over-year and EPS growth of 1.44% year-over-year. On the balance sheet, it maintains a current ratio of 18.86x, a quick ratio of 18.45x, working capital of $200.77M, a debt-to-equity ratio of 0.07x, a debt ratio of 0.06, free cash flow of $-55.14M (TTM), and net debt of $-12.91M. Figures sourced from SEC EDGAR.
- Market Cap
- $904.45M
- P/E TTM
- -12.78x
- EPS TTM
- $-1.13
- P/B TTM
- 4.48x
- ROE TTM
- -34.13%
- ROA TTM
- -32.33%
- Debt To Equity
- 0.07x
- Free Cash Flow TTM
- $-55.14M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Design Therapeutics, Inc. in?
Design Therapeutics, Inc. (DSGN) operates in the Pharmaceutical Preparations industry.
What exchange does DSGN trade on?
Design Therapeutics, Inc. (DSGN) trades on the Nasdaq.
Where is Design Therapeutics, Inc. incorporated?
Design Therapeutics, Inc. is incorporated in DE.
When was Design Therapeutics, Inc. (DSGN)'s most recent SEC filing?
Design Therapeutics, Inc. (DSGN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-03.
What is DSGN's market cap?
Design Therapeutics, Inc. (DSGN) has a market capitalization of $904.45M as of 2026-06-30.
What is DSGN's EPS (earnings per share)?
Design Therapeutics, Inc. (DSGN)'s trailing twelve month EPS is $-1.13 as of 2026-06-30.
What is DSGN's ROE (return on equity)?
Design Therapeutics, Inc. (DSGN)'s trailing twelve month Return on Equity (ROE) is -34.13% as of 2026-06-30.
What is DSGN's ROA (return on assets)?
Design Therapeutics, Inc. (DSGN)'s trailing twelve month Return on Assets (ROA) is -32.33% as of 2026-06-30.
What is DSGN's ROIC (return on invested capital)?
Design Therapeutics, Inc. (DSGN)'s trailing twelve month Return on Invested Capital (ROIC) is -41.52% as of 2026-06-30.
What is DSGN's EV/EBITDA?
Design Therapeutics, Inc. (DSGN)'s trailing twelve month EV/EBITDA is -11.32x as of 2026-06-30.